Stivarga regorafenib Logo
Bayer Logo

Please follow this 3-step process to retrieve the copay information. At the end of the process, please print the co-pay information and provide it to your healthcare team or specialty pharmacy.

Step 1: Verify Eligibility

 

1.I am a United States Resident.
2.I am over 18 years old.
3.My doctor has prescribed STIVARGA®.
4.I currently have private or commercial health insurance for a portion of my prescription drug cost.
5.I certify that I am NOT enrolled in any federal or state subsidized healthcare program that covers a portion of my prescription drug costs, including Medicare (such as Medicare Part D prescription drug benefit), Medicaid, TRICARE, or any other federal or state healthcare plan, including pharmaceutical assistance programs.
6.I certify that I will not seek reimbursement for STIVARGA® from any third party payer such as a flexible spending account, a healthcare savings account or a health reimbursement account.

STIVARGA® $0 CO-PAY PROGRAM TERMS & CONDITIONS

  • Patients are eligible if they are commercially insured and may pay as little as $0 per month up to the program maximum. Benefit limitations apply.
  • The program is not available for patients who: (i) are enrolled in Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program; (ii) are not using insurance coverage at all; (iii) are enrolled in an insurance plan that reimburses for the entire cost of the drug; or (iv) where product is not covered by patient's insurance
  • Use of the program must be consistent with and not prohibited by the requirements of the patient's health insurance requiring notification to his or her payor of the existence and/or value of this offer
  • The program does not cover costs associated with a patient visit including prescriber, staff, or administrative charges associated with administering the applicable Bayer product
  • Patient agrees to provide necessary health information to the administrators of the STIVARGA® $0 Co-pay Program
  • Offer valid only for patients 18 years and over treated in the USA, including Puerto Rico, Guam and US Territories
  • Bayer reserves the right to rescind, revoke, amend, determine eligibility, or monitor participation of the program at any time with or without notice
  • The STIVARGA $0 Copay Program is not insurance. This program may not be combined with any third-party rebate, coupon, or offer, and may not be redeemed for cash
  • Cash Discount cards and other non-insurance plans are not valid as primary under this offer
  • It is illegal to (or offer to) sell, purchase, or trade this offer. This offer is not transferable and is limited to one offer per person. Not valid if reproduced. Void where prohibited by law.
  • For questions about the STIVARGA $0 Co-pay Program, call for support at 1-866-581-4992

Indications and Important Safety Information

INDICATIONS

STIVARGA (regorafenib) is a prescription medicine used to treat adults with:

  • colon or rectal cancer that has spread to other parts of the body and for which they have received previous treatment with certain chemotherapy medicines
  • a rare stomach, bowel, or esophagus cancer called GIST (gastrointestinal stromal tumor) that cannot be treated with surgery or that has spread to other parts of the body and for which they have received previous treatment with certain medicines
  • a type of liver cancer called hepatocellular carcinoma (HCC) in people who have been previously treated with sorafenib

It is not known if STIVARGA is safe and effective in children less than 18 years of age.

IMPORTANT SAFETY INFORMATION

STIVARGA (regorafenib) can cause severe liver problems, including increased blood ammonia, which can sometimes lead to death. Your healthcare provider will do blood tests to check your liver function before you start taking STIVARGA and during your treatment with STIVARGA to check for liver problems.

Tell your healthcare provider right away if you get any of these signs or symptoms of liver problems during treatment:

  • yellowing of your skin or the white part of your eyes (jaundice)
  • pain on the upper right side of your stomach area (abdomen)
  • nausea or vomiting
  • loss of appetite
  • light-colored stools (bowel movements)
  • dark “tea-colored” urine
  • severe headache or headaches that persist
  • vision changes
  • seizures
  • feeling more tired than usual
  • drowsiness
  • trembling
  • confusion
  • memory loss or disorientation

Before taking STIVARGA, tell your healthcare provider about all of your medical conditions, including if you:

  • have liver problems in addition to liver cancer
  • have bleeding problems
  • have high blood pressure
  • have heart problems or chest pain
  • plan to have surgery or have had a recent surgery. You should stop taking STIVARGA at least 2 weeks before planned surgery
  • are pregnant or plan to become pregnant. STIVARGA can harm your unborn baby.
    • Females should use effective birth control during treatment with STIVARGA and for 2 months after your final dose of STIVARGA. Tell your healthcare provider right away if you become pregnant during treatment with STIVARGA or within 2 months after your final dose of STIVARGA.
    • Males with female partners who can become pregnant should use effective birth control during treatment with STIVARGA and for 2 months after your final dose of STIVARGA.
  • are breast-feeding or plan to breast-feed. It is not known if STIVARGA passes into your breast milk. Do not breastfeed during treatment with STIVARGA and for 2 weeks after your final dose of STIVARGA.

Tell your healthcare provider about all the prescription and over-the-counter medicines, vitamins, and herbal supplements you take. Avoid drinking grapefruit juice and taking St. John’s Wort while taking STIVARGA.

STIVARGA may cause serious side effects, including:

  • infection. STIVARGA may lead to a higher risk of infections especially of the urinary tract, nose, throat and lung. STIVARGA may lead to a higher risk of fungal infections of the mucous membrane, skin or the body. Tell your healthcare provider right away if you get fever, severe cough with or without an increase in mucus (sputum) production, severe sore throat, shortness of breath, burning or pain when urinating, unusual vaginal discharge or irritation, redness, swelling or pain in any part of the body.
  • severe bleeding. STIVARGA can cause bleeding, which can be serious and sometimes lead to death. Tell your healthcare provider if you have any signs of bleeding while taking STIVARGA, including: vomiting blood or if your vomit looks like coffee grounds, pink or brown urine, red or black (looks like tar) stools, coughing up blood or blood clots, menstrual bleeding that is heavier than normal, unusual vaginal bleeding, nose bleeds that happen often, bruising, and lightheadedness.
  • a tear in your stomach or intestinal wall (bowel perforation). STIVARGA may cause a tear in your stomach or intestinal wall (bowel perforation) that can be serious and sometimes lead to death. Tell your healthcare provider right away if you get severe pains or swelling in your stomach area (abdomen), fever, chills, nausea, vomiting, or dehydration.
  • a skin problem called hand-foot skin reaction and severe skin rash. Hand-foot skin reactions are common and sometimes can be severe. Tell your healthcare provider right away if you get redness, pain, blisters, bleeding, or swelling on the palms of your hands and soles of your feet, or a severe rash.
  • high blood pressure. Your blood pressure should be checked every week for the first 6 weeks of starting STIVARGA. Your blood pressure should be checked regularly and any high blood pressure should be treated while you are receiving STIVARGA. Tell your healthcare provider if you have severe headaches, light-headedness, or changes in your vision.
  • decreased blood flow to the heart and heart attack. Get emergency help right away if you get symptoms such as chest pain, shortness of breath, feel dizzy, or feel like passing out.
  • a condition called Reversible Posterior Leukoencephalopathy Syndrome (RPLS). Call your healthcare provider right away if you get severe headaches, seizure, confusion, change in vision, or problems thinking.
  • risk of wound healing problems. Wounds may not heal properly during STIVARGA treatment. Tell your healthcare provider if you plan to have any surgery before starting or during treatment with STIVARGA.
    • You should stop taking STIVARGA at least 2 weeks before planned surgery.
    • Your healthcare provider should tell you when you may start taking STIVARGA again after surgery.

The most common side effects with STIVARGA include pain including stomach-area (abdomen); tiredness, weakness, fatigue; diarrhea (frequent or loose bowel movements); decreased appetite; infection; voice change or hoarseness; increase in certain liver function tests; fever; swelling, pain, and redness of the lining in your mouth, throat, stomach, and bowel (mucositis); and weight loss.

Call your healthcare provider for medical advice about side effects. You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

For important risk and use information about STIVARGA, please see the full Prescribing Information, including Boxed Warning.

Bayer Logo

© 2026 Bayer. All rights reserved.
BAYER, the Bayer Cross, REACH and STIVARGA are registered trademarks of Bayer.

Last Modified 09/2026